Zavzpret

Gepant, CGRP receptor antagonist

Zavzpret

Zavzpret (zavegepant)

Zavzpret (zavegepant) is the first intranasally administered CGRP receptor antagonist (gepant), FDA-approved in March 2023 for the acute treatment of migraine in adults. Its nasal route delivers faster onset than oral gepants, useful when nausea precludes pills.

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Gepant, CGRP receptor antagonist

Common uses

Acute treatment of migraine with or without aura in adults

Pharmacy

Starting dose

10 mg (one spray) intranasally in one nostril

Preparations

10 mg/spray nasal solution

US FDA Max

10 mg per 24 h

Pharmacology

Routes

Intranasal

Onset

Pain relief reported within 15 min in trials

Duration

~48 h sustained pain freedom in responders

Half-life

~6.6 h

Bioavailability

~5% intranasal

Pregnancy

Limited data; avoid

Legal status

Rx

Purported mechanism

Small-molecule CGRP receptor antagonist; intranasal formulation